Effect of Acid‐Suppressive Strategies on Pazopanib Efficacy in Patients With Soft‐Tissue Sarcoma

Pazopanib (PAZ), a tyrosine kinase inhibitor used in the treatment of soft tissue sarcoma (STS), should not be administered with acid‐suppressive medications (ASMs) due to decreased drug solubility. Common practice for patients requiring ASM with PAZ is to separate administration by 12 hours; howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Pisano, Sorana G., Hoffman, Sarah E., Legasto, Carlo S., McLaughlin, Eric M., Porter, Kyle, Chen, James L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742936/
https://www.ncbi.nlm.nih.gov/pubmed/31264782
http://dx.doi.org/10.1111/cts.12648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742936/
https://www.ncbi.nlm.nih.gov/pubmed/31264782
http://dx.doi.org/10.1111/cts.12648

Ejemplares similares